Terameprocol

Terameprocol is an inhibitor targeting the Sp1 transcription factor, which can selectively inhibit the transcription of Sp1-dependent genes. Terameprocol exerts its effects by inhibiting Sp1-mediated gene transcription, such as reducing the expression of genes like CDC2, survivin and HMGB1, thereby arresting the cell cycle, inducing apoptosis, and suppressing the inflammatory response. Terameprocol exhibits anti-proliferative, pro-apoptotic, and anti-inflammatory activities and is currently mainly used in the research of diseases such as cancer and pulmonary arterial hypertension[1][2][3].

Product Specifications

CAS Number

[24150-24-1]

Product Name Alternative

EM-1421

UNSPSC

12352005

Hazard Statement

H410

Target

Apoptosis; COX; Survivin; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/terameprocol.html

Purity

99.33

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=CC(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)=CC=C1OC

Molecular Formula

C22H30O4

Molecular Weight

358.47

Precautions

H410

References & Citations

[1]Eads D, et al. Terameprocol, a methylated derivative of nordihydroguaiaretic acid, inhibits production of prostaglandins and several key inflammatory cytokines and chemokines. J Inflamm (Lond) . 2009 Jan 8;6:2.|[2]Sun Y, et al. Terameprocol (tetra-O-methyl nordihydroguaiaretic acid), an inhibitor of Sp1-mediated survivin transcription, induces radiosensitization in non-small cell lung carcinoma. J Thorac Oncol. 2011 Jan;6 (1) :8-14.|[3]Nogueira-Ferreira R, et al. HMGB1 down-regulation mediates terameprocol vascular anti-proliferative effect in experimental pulmonary hypertension. J Cell Physiol. 2017 Nov;232 (11) :3128-3138.